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Abstract
RNA interference (RNAi) has been considered as an efficient therapeutic approach against the human immunodeficiency
virus type 1 (HIV-1). However, to establish a durable inhibition of HIV-1, multiple effective short hairpin RNAs (shRNAs) need
to be stably expressed to prevent the emergence of viral escape variants. In this study, we engineered a randomized
lentiviral H1-promoter driven shRNA-library against the viral genome. Potent HIV-1 specific shRNAs were selected by
ganciclovir treatment of cell lines stably expressing the cDNA of Herpes Simplex Virus thymidine kinase (HSV-TK) fused to
HIV-1 nucleotide sequences. More than 50% of 200 selected shRNAs inhibited an HIV-1 based luciferase reporter assay by
more than 70%. Stable expression of some of those shRNAs in an HIV-1 permissive HeLa cell line inhibited infection of wild-
type HIV-1 by more than 90%. The combination of a randomized shRNA-library directed against HIV-1 with a live cell
selection procedure yielded non-toxic and highly efficient HIV-1 specific inhibitory sequences that could serve as valuable
candidates for gene therapy studies.
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Introduction
RNAi is a highly conserved process that protects the host from
transposable elements and viruses [1,2]. In mammalian cells,
RNAi can be initiated by the introduction of synthetic double
stranded short interfering RNAs (siRNAs) of 19–21 basepairs,
which are recognized by the cytoplasmic RNA induced silencing
complex (RISC) and trigger the specific degradation of comple-
mentary mRNA, thereby circumventing an interferon response
[3]. Besides its role as an experimental technique for loss-of-
function studies [4,5], RNAi emerges as a powerful therapeutic
approach towards human diseases as well as viral infections [6,7].
Different vectors have been developed both for transient and
stable expression of the inhibitory RNA species [8], more
commonly by RNA Polymerase III driven transcription of the
inverted sense and antisense strands of shRNAs, connected by a
linker-sequence (loop) [9,10]. In the case of HIV-1, siRNA- and
shRNA-mediated post-transcriptional gene silencing offers a
promising strategy to inhibit viral replication at different stages
of viral infection by targeting viral as well as host genes
[11,12,13,14]. However, the stable expression of antiviral shRNAs
did not evoke the expected long-term inhibition of the virus due to
the emergence of viral escape mutants [15,16,17]. To circumvent
the emergence of RNAi-resistant variants it seems to be
mandatory to identify multiple potent inhibitory sequences
targeting different or conserved regions of the viral genome
[18,19,20,21].
There are several publicly available design algorithms [22,23],
but reliable rules for efficient siRNA-sequences are still missing
and designed siRNAs need to be assayed for their inhibitory
potential and possible cytotoxic or other off-target effects [24].
Furthermore, the costly and time-consuming synthesis and
validation of designed siRNAs limit their use in large-scale studies.
Consequently, several groups have developed techniques for the
generation of randomly prepared shRNA libraries [25,26,27]. All
these approaches employ a similar principle for the construction of
the library: cDNA is enzymatically converted to short inverted
repeats separated by a linker-sequence and transcribed into
shRNAs by appropriate expression systems. However, the
feasibility and efficiency of these techniques has been disputed
[28].
We have adopted and modified these technologies to generate
the first randomized shRNA-library against the HIV-1 genome. A
stringent cell-based selection procedure was introduced, which
allowed for the identification of novel and potent HIV-1 specific
shRNAs with little or no host cell toxicity. Moreover, a range of
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13172these virus-specific shRNAs were applied as synthetic siRNAs with
a comparable efficacy. Additionally, the same sequences were
stably expressed in permissive HeLa CD4 (HeLa P4) cell lines
[29], where they effectively inhibited wild-type HIV-1 infections.
Thus, our data demonstrate for the first time that a straightfor-
ward shRNA-library construction protocol in line with a stringent
cellular selection procedure yield potent and readily convertible
shRNAs against a viral genome.
Materials and Methods
Construction of the shRNA-library
The construction of the shRNA-library can be divided into 7
steps. Step 1: 5 mg viral DNA (pNL4.3; NIH AIDS Research
and Reference Reagent Program) was partially digested with
1610
23 U DNaseI in the presence of 1 mM MnCl2 (109,3 7 uC).
DNaseI was inactivated by vortexing (300) and heat-inactivation
(109,6 5 uC). Cleaved 59 and 39 ends were repaired with 5 U T4
DNA Polymerase and 10 U Klenow Fragment in the presence of
200 mM dNTPs. DNA was separated on 20% polyacrylamid in
TBE and fragments of the appropriate size (150–300 bp) were
isolated by diffusion in 0.5 M NaCl; 1 mM EDTA (1h, 50uC,
shaking) and purified by EtOH precipitation. Step 2: 4.5 mgo f
the DNA was ligated to 1.5 mg of the 39loop. Subsequently the T4
ligase was heat-inactivated (109,6 5 uC) and the DNA was digested
with MmeI (1h, 37uC). The reaction was separated on 20%
polyacrylamid in TBE and the product of 39 loop and gene
fragment was isolated and purified. The PAGE-purified 39 loop
(59-GTTGAATCCCGGTTCAAGAGACCGGGATCCAAC) was
purchased from QIAGEN (Hilden, Germany) and contained a
MmeI restriction enzyme site. Step 3: 1 mg of the purified DNA
fragment was ligated to 500 ng 59loop. The reaction was separated
on 20% polyacrylamid in TBE and the single-stranded circular
DNA ring of 39 loop, gene fragment and 59 loop was isolated and
purified. The PAGE-purified 59loop (59-GGAGAGACTCACTG-
GCCGTCGTTTTACCAGTGAAGATCTCCNN)waspurchased
from Qiagen. Step 4: The purified DNA ring was used for a RCA
using 10 U W29 Polymerase and the 59loop specific primers RCA1
(59-ACTGGTAA) and RCA2 (59-GCCGTCGT) in the presence of
0.01 U Pyrophosphatase and 200 mM dNTPs (o.n., 30uC). The
RCA products were digested with BglII and MlyI (1h, 37uC) and
separated on 20%polyacrylamid inTBE.The palindromic,inverted
repeats were isolated and purified. Step 5: 10 ng of the BglII-MlyI –
digested fragments were ligated to 100 ng of pENTR/shLib. The
transformedbacterialcolonies were pooled and the primaryshRNA-
library isolated. Step 6: The isolated plasmids were digested with
BamHI and re-ligated (pENTR/shLib -BamHI). The resulting
bacterial colonies were pooled as the secondary shRNA-library.
Step 7: The shRNA-expression cassettes were subcloned into
pLPac/shLib (LR Clonase
TM II Enzyme Mix, Invitrogen, Karls-
ruhe, Germany).
Generation of pENTR/siLib
pENTR/ siH1/mDD-stuffer [30] was linearized with BbsI and
the resulting 59 T-overhangs were blunt-ended using 5 U T4 DNA
Polymerase in the presence of 200 mM dATP. After digestion with
BglII, shRNA-sequences were ligated between the H1-Promoter
and the polyT cassette.
Generation of pENTR/TA
2 inverted Xcm I restriction enzyme sites were created by
annealing 36 nt single-stranded oligonucleotides with 59BamHI
and 39HindIII overhangs (MWG, sequences on request) and
ligated into pENTR/siH1/mDD-stuffer. Digestion of the
pENTR/TA with XcmI allows for TA-cloning of the Taq-
Polymerase amplified shRNA-expression cassettes.
Generation of pLP/EGFP/siLib
The puromycin-gene was PCR-amplified from pPGK-puro
(K. Rajewski, Harvard medical school; primer-sequences on
request). The PCR-product was digested with SmaI and Bpu1102I
and ligated into the GATEWAYH compatible lentiviral vector pL
[30].
Generation of selection constructs
The HSV-TK gene was PCR-amplified from pRapid-flirt (A.
Waisman, Medical Hospital Mainz, [30]) and ligated into
pENTR/siH1/mDD-stuffer to yield pENTR/TK. Afterwards,
three overlapping HIV-1 genomic segments were PCR-amplified
and ligated between HSV-TK ORF and the polyA to yield the
selection constructs pENTR/TK/HIV-Lib1, pENTR/TK/HIV-
Lib2 and pENTR/TK/HIV-Lib3, respectively (primer-sequences
on request). The selection cassettes were next subcloned into the
lentiviral vector pL by means of LR Clonase
TM II Enzyme Mix
(Invitrogen, Karlsruhe, Germany).
Production of lentiviral particles
The production of lentiviral particles was performed as
described in the Manual ‘ViraPower
TM Lentiviral Expression
System’ (Invitrogen, Karlsruhe, Germany).
Generation of stable cell lines
HeLa wt or HeLa P4 cells were transduced with viral particles
at a (MOI: 0.1) in the presence of 6 mg/ml polybrene. 48h post
transduction, cells were treated with 10 mg/ml blasticidin for 10
days. Surviving clones were expanded in 3 mg/ml blasticidin and
analysed for stable integration of the transgene and expression of
HSV-TK protein and the fusion-mRNAs.
Selection of efficient HIV-1 specific shRNAs
The library selection cell lines HeLa
TK/HIV-LIB1,H e L a
TK/HIV-LIB2
and HeLa
TK/HIV-LIB3 were transduced with lentiviral particles of the
relevant shRNA-libraries (MOI: 0.1). 48h post transduction, selection
cell lines were treated two days with 1mg/ml puromycin followed by
ganciclovir treatment (2610
26 M) for 5 days, replacing the selection
media each day. Surviving cells were expanded clonally and the
integrated shRNAswererecovered bynested PCR (primersequences
on request).
Western blot analysis
Equal amounts of proteins were probed either with HSV-TK
antibody (W.C. Summers, Yale University), HIV-1 Integrase
antibody (acris antibodies, Herford, Germany), Hsp70 antibody
(BD Pharmingen, Heidelberg, Germany) or b-actin antibody
(Sigma-Aldrich, Muenchen, Germany), and with horse-radish
peroxidase-conjugated antibody to rabbit or mouse IgG (Sigma-
Aldrich, Muenchen, Germany) as the primary and secondary
antibodies in blocking buffer (10% milk in TBS), respectively.
mRNA isolation and Northern Blot analysis
Total RNA was isolated using TRIZOLH (Invitrogen, Karls-
ruhe, Germany). Enrichment of mRNA was achieved with the
NucleoTrap mRNA kit (Macherey-Nagel, Du ¨ren, Germany). 1 mg
mRNA was separated on denaturing 1.8% Agarose in MOPS
buffer and transferred onto positively charged nylon membranes
in 206SSC. Membranes were pre-hybridized (4h, 65uC) and
hybridized with
32P-labeled HSV-TK cDNA probe (overnight,
Potent HIV-1 Specific shRNAs
PLoS ONE | www.plosone.org 2 October 2010 | Volume 5 | Issue 10 | e1317265uC). Washed membranes were exposed to Phosphoimager
screens.
Luciferase activity assays
HEK 293 FT cells (Invitrogen, Karlsruhe, Germany) were co-
transfected with either PCR-amplified shRNA-expression cassettes
or shRNA-expressing vectors and pNL4.3Luc.R-E- (NIH AIDS
Research and Reference Reagent Program). Luciferase expression
was measured 48h post transfection using the Luciferase Assay
Reporter Kit (Promega, Mannheim, Germany) and normalized to
total protein.
Sequencing
The PCR amplified shRNA expression cassettes were cloned
into pENTR/TA and sequenced via TouchDown-PCRs using the
BigDyeH Terminator v3.1 Cycle Sequencing Kit in combination
with the dGTP BigDyeH Terminator v3.1 Cycle Sequencing Kit
(both applied biosystems) in a ratio of 3:1 and in the presence of
0.83 M Betaine.
IFN-b and P24 antigen ELISAs
IFN-b ELISAs (PBL Biomedical Laboratories, Piscataway, NJ)
and p24 ELISAs (Aalto Bio Reagents Ltd., Dublin, Ireland) were
performed as described by manufacturers instructions.
Detection of cell death via crystal violet staining
3610
3 cells were seeded overnight per well of a 96 well plate.
Adherent cells were quantified with crystal violet dye as previously
described [30] for up to 5 days and normalized to day 1.
Results
Construction of a randomized shRNA-library targeting
the HIV-1 genome
The construction of the randomized lentiviral shRNA-library
against HIV-1 was based on a previously described technology
with some modifications [26]. The consecutive enzymatic steps to
produce the shRNA-library based on the cDNA of HIV-1 are
shown in Figure 1 and are described in detail in the Material and
Method section. In order to circumvent the production of wild-
type virus in selection cell lines, the HIV-1 genome (pNL4.3) was
divided into three internal overlapping segments, comprising all
genes of HIV-1. The three parts HIV-1.1 (2.5 kb), HIV-1.2
(2.5 kb) and HIV-1.3 (2.8 kb) comprised the NL4.3 nucleotides
855–3374, 3297–5796 and 6067–8447, respectively. In order to
maximize the diversity of the shRNA-library, the HIV-1 segments
were randomly fragmented with DNase I (Fig. 1a) which exhibits
only minor if any sequence specificity [31,32]. Blunted fragments
of about 150–300 bp were ligated to the 39loop which connects
the final sense and antisense strands and enables the restriction of
the target sequence to 20 basepairs by the insertion of the Mme I
recognition site at the start of its stem (Fig. 1b). The subsequent
ligation of the 59loop produces single-stranded DNA rings which
were amplified by rolling circle amplification (RCA) to concate-
mers of inverted repeats that are flanked by Bgl II and Mly I
restriction sites (Fig. 1c–d). The resulting palindromic, inverted
repeats encoding shRNA molecules were inserted downstream of
the RNA Polymerase III Promoter H1 derived from pSUPER
[33] and upstream of the poly-T termination site of the
GATEWAYH compatible linearized vector pENTR/shLib
(Fig. 1e, primary library). Excess 39 loops were removed by diges-
tion with Bam HI. The following religation yielded expression-
ready shRNA-vectors (Fig. 1e, secondary library). To generate the
final HIV-1 shRNA-library, the shRNA-sequences were subcloned
by LR recombination into the lentiviral vector pLP/EGFP/shLib
(Fig. 1e, final library) which allows for the enrichment of transduced
cell lines by puromycin selection and fluorescence monitoring by
means of enhanced green fluorescence protein (EGFP).
The combined complexity of the primary libraries was about
1.4610
4 (1750 colonies per kB of cDNA). Sequencing of 10
individual clones revealed 10 different HIV-1 specific shRNA-
sequences consisting of sense and antisense strand as well as the
loop sequence (not shown). Thus, our modifications allowed us to
elevate the complexity of our shRNA-library as compared to the
original technology, which utilized restriction enzymes for
fragmentation of target DNA. Furthermore, we amplified the
number of colonies by a factor of about 10 in order to maintain the
complexity of the libraries throughout the subsequent cloning steps
(Table 1). Hence, our data suggest that the randomization of a
cDNA by DNaseI produces a broader diversity and complexity of
a given library [26].
Generation and validation of library selection cell lines
In order to maximize the stringency of the selection scheme, our
method employed a fourfold combination of negative/positive
selection measures, comprising ganciclovir (negative) [27] and
blasticidin selection of stable selection cell lines (Fig. 1a) in line
with selection of the shRNA library via puromycin, and EGFP
fluorescence (positive), respectively. Several stably transduced
HeLa selection clones (HeLa
TK/HIV-LIB1, HeLa
TK/HIV-LIB2 and
HeLa
TK/HIV-LIB3) were shown to express the HSV-TK protein
(Fig. 2b) and to be functional by means of ganciclovir induced cell
death, as visualised by crystal violet staining of adhering cells
(Fig. 2c). Furthermore, we tested if our pooled lentiviral shRNA
library is able to downregulate the HSV-TK expression in the
corresponding selection cell lines. Upon transient transfection of
the shRNA libraries into the selection cell line clones indicated by
asterisks in Fig. 2c, only the complementary library is capable of
downregulating the HSV-TK expression significantly as compared
to the non-matching libraries (Fig. 2d).
Furthermore, the proper expression of the fusion-mRNAs was
verified by Northern blot analysis of mRNA from these selection
cell lines using a HSV-TK specific probe (Fig. 2e). Finally, we
show that in the presence of puromycin and gancyclovir only the
transduction of a relevant shRNA-library into the corresponding
selection cell line enables the transduced cells to proliferate and
form colonies, suggesting that our selection design represents a
highly stringent procedure for the selection of shRNA-libraries
(Fig. 2f).
Selection of potent HIV-1 specific shRNAs
The lentiviral shRNA-libraries were stably transduced into the
corresponding selection cell lines and treated with ganciclovir in
order to select for potent shRNAs. Transduced cells were then
treated with puromycin and only surviving, EGFP positive
colonies were picked for analysis. Next, shRNAs were recovered
by nested PCR amplification of shRNA-expression cassettes [34]
from the genomic DNA of surviving cell clones. PCR amplified
shRNA cassettes were subjected to co-transfections into HEK 293
FT cells along with the HIV-1 specific luciferase reporter construct
pNL4.3luc.R-E-. Of the 200 individual cassettes tested, more than
50% inhibited luciferase activity by over 70% as measured 48h
post transfection and are thus considered as effective (Fig. 3a).
To enable a vector-based expression of those shRNA-sequences
we subcloned a collection of highly potent PCR-amplified shRNA-
expression cassettes into the GATEWAYH compatible TA-cloning
vector pENTR/TA. 36 recovered shRNA-expression cassettes
Potent HIV-1 Specific shRNAs
PLoS ONE | www.plosone.org 3 October 2010 | Volume 5 | Issue 10 | e13172Figure 1. Construction of the shRNA-library. a) The 3 HIV segments of pNL4.3 were fragmented using DNaseI and blunt-ended. b) Fragments of
150–300 bp were eluted and ligated to the 39 loop. To limit the size of the HIV-1 inverted repeats, a recognition site for MmeI, which cleaves exactly
20nt from its recognition site and leaves 2 nt 59 overhangs, was engineered into the 39 loop. c) Ligation of the 59 loop to the MmeI-digested
fragments generated a quasi-circular single-stranded structure. d) Rolling circle amplification (RCA) reactions using W 29 DNA polymerase and the
primers RCA1 and RCA2 were performed to amplify the single-stranded circular DNA and to generate the complementary strand yielding a DNA
concatemere of palindromic, inverted repeats encoding siRNA molecules. Digestion with BglII and MlyI liberated shRNA sequences which were
inserted into the expression vector pENTR/siLib. d) The shRNA sequences were cloned into the linearized pENTR/Lib generating the primary library
which was religated after BamHI digestion yielding the secondary library. The final lentiviral shRNA-library was generated by LR recombination of the
secondary library into pL/EGP/siLib.
doi:10.1371/journal.pone.0013172.g001
Table 1. Clone size of randomized shRNA-libraries.
primary library pENTR/siLib secondary library pENTR/siLib final library pL/EGFP/siLib
library 1 4.5610
3 cfu 1.6610
4 cfu .10
5 cfu
library 2 3.4610
3 cfu 1.4610
4 cfu .10
5 cfu
library 3 6610
3 cfu 1.5610
4 cfu .10
5 cfu
To indicate the complexity of the shRNA library, the number of bacterial colonies of each transformation step (primary library, secondary library and final library) was
documented as colony forming units (cfu).
doi:10.1371/journal.pone.0013172.t001
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the HIV-1 specific luciferase assay described above (Fig. 3b). The
relative nucleotide positions and HIV-1 target sequences of this
selection are depicted in Figure 3b and Table 2. 24 individual
shRNAs were directed against the gag (g) and gag-pol transcript (g/
p), 2 shRNAs against vif (vif), one against rev (revE1) and one
against env (env), respectively. Subsequent BLAST analysis against
the HIV-sequence data base of the Los Alamos National Laboratory
(http://www.hiv.lanl.gov) revealed that some shRNAs target well
conserved HIV-1 sequences, whereas some target more variable
regions. It is worth emphasizing that none of our shRNA-
sequences has been described so far, pushing us to analyse the
selected sequences using RNAi design algorithms [24]. Interest-
ingly, none of our sequences matched all parameters of those
algorithms, suggesting that there are still unknown sequence
characteristics for potent siRNAs and shRNAs.
Figure 2. Generation of HIV-1 specific selection cell lines. a) HeLa selection cell lines stably express a fusion-mRNA consisting of the HSV-TK
upstream of a untranslated fragment of the HIV-1 genome (pNL4.3), that acts as target mRNA for the shRNA-library. Only cells which express an
efficient HIV-1 directed shRNA do not express HSV-TK and are able to proliferate. b) Western blot analysis of stably transduced HeLa selection cell
lines with a HSV-TK specific antibody. Parental HeLa cells were used as control. c) Selection cell lines and HeLa wt cells were functionally analysed by 8
days of ganciclovir (GCV: 2610
25 M) treatment. Surviving cells were stained with crystal violet. Designated clones (*) were used to select the shRNA-
library. d) Western blot analysis of HSV-TK expression in HeLa selection cell lines transiently transfected with pooled shRNA-libraries. Only relevant
libraries downregulate HSV-TK in the corresponding selection cell line. e) Expression of the fusion-mRNA was examined by Northern blot analysis
with a HSV-TK specific probe. f) Transduction and subsequent puromycin (2 days) and GCV-selection (5 days) of a relevant (shLib2) and not of an
irrelevant shRNA-library (shLib3) allows for clonal expansion of transduced cells.
doi:10.1371/journal.pone.0013172.g002
Potent HIV-1 Specific shRNAs
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yielded a high proportion of potent inhibitory shRNAs that are
unique in their sequence preferences as compared to those
predicted by publicly available design algorithms.
Antiviral activity and cellular tolerance of siRNA and
lentiviral shRNA derivatives
In eukaryotic cells, shRNAs are transcribed in the nucleus and
exported to the cytoplasm by exportin-5 where they are processed
into functional siRNAs by Dicer [35]. For that reason, we
expected a similar inhibitory potential of exogenously adminis-
tered siRNA derivatives compared to their equivalent vector based
shRNAs. 11 effective shRNA sequences were randomly selected
and synthesized as siRNAs to be co-transfected with the
corresponding selection constructs into HEK 293 FT cells.
Western blot analysis revealed that all of them were able to
inhibit the TK expression from the HSV-TK/HIV fusion-mRNA
constructs even at the lowest concentration used (Fig. 4a),
demonstrating that our shRNA sequences could also be converted
to efficient siRNAs.
It has been described that some short inhibitory sequences may
exert a cytotoxic effect which was linked to the interferon (IFN)
type I responses (IFN-a and IFN-b) [36,37]. In order to test our
sequences in that regard, we performed IFN-b ELISAs on HeLa
cells transfected with the siRNA as described previously [38]. Even
at the highest concentration used none of the above sequences
induced detectable levels of IFN-b (Fig. 4b).
In addition, we investigated the inhibitory potential of the
identified shRNA sequences with regard to wild-type HIV-1
infections. The corresponding 11 shRNAs were subcloned into the
lentiviral vector pL and stably transduced into HIV-1 permissive
HeLa P4 cells. Stable shRNA-expressing clones were infected with
wt HIV-1 and the amount of the HIV-1 capsid protein p24 was
determined in the culture supernatants by p24-antigen ELISA
42 h post infection. As shown in Fig. 4c, all cell clones expressing
the verified shRNAs showed a significant reduction of p24 in the
culture supernatant in comparison to cell clones expressing an
HIV-1 irrelevant shRNA (scr). Finally, we investigated whether
stable lentiviral expression of the shRNAs may have any
detrimental cellular effects. As shown in Fig. 4d, none of the
shRNAs impaired the division rate of the corresponding cell line
Figure 3. Reconfirmation of the inhibitory potential of selected shRNA-sequences. a) ShRNAs were PCR-amplified from genomic DNA of
selected cell clones as shRNA expression cassettes consisting of H1 promoter, shRNA-sequence and polyT. Each of the 200 individual cassettes were
co-transfected with the HIV-1 specific Luciferase reporter construct pNL4.3Luc.R-E- into HEK 293 FT cells. Luciferase expression was measured 48 h p.t.
Cells transfected with pNL4.3Luc.R-E- and a scrambled shRNA (sh scr) expressing cassette were used as control. b) Map of the identified shRNAs and
re-evaluation of their inhibitory potential upon co-transfection as described in a). Cells which were transfected with pNL4.3LucR-E- alone or co-
transfected with a scrambled siRNA control served as controls. Error bars indicate +/2 SD of mean of three independent experiments.
doi:10.1371/journal.pone.0013172.g003
Potent HIV-1 Specific shRNAs
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staining of adherent cells through four days of culture. Taken
together, our data indicate that our selected shRNAs can be
converted to potent siRNAs and exert a high inhibitory effect on
wt HIV-1 infections, when stably expressed, both without any
detectable cytotoxicity.
Comparison of H1- and U6-promoter driven shRNA-
expression
To develop an effective RNAi-based gene therapy against HIV-
1, a combinatorial approach using several shRNAs expressed from
different polymerase III promoters is supposed to be mandatory
[39]. To this end, we tested the human U6 promoter for
expression of our shRNA sequences and compared its activity
against H1 promoter driven shRNA expression. Western blot
analysis of integrase gene expression after co-transfection of the
shRNA vectors in combination with pNL4.3R-E-Luc revealed
that there is no significant difference in the efficacy of the two
promoters tested (Fig. 5a).
Additionally, we compared our newly identified shRNAs with
previously reported anti-HIV shRNAs. For this purpose, we
generated plasmids for U6 promoter driven shRNAs against gag/
pol, nef, rev and vpu/enf. The shRNAs against gag/pol [20] as
well as vpu/env [18] were directed at highly conserved regions of
the HIV-1 genome, whereas shNef [12] has been designed
according to the siRNA algorithm provided by Dharmacon and
the shRev [13] has been chosen due to the accessibility of the
target mRNA. As shown in Fig. 5b, shRNAs selected from our
randomized shRNA-library show comparable inhibitory potential
to the published shRNA sequences. To confirm this observation,
we quantified the inhibitory potential of the shRNAs by
performing luciferase assays on the lysates (Fig. 5c). Together,
these results demonstrate that our highly potent HIV-1 specific
shRNA sequences exert comparable efficacy as to the published
sequences. They could also be expressed from different promoters,
which suggest them as possible candidates for combinatorial gene-
therapeutic approaches against HIV-1.
Discussion
RNA interference by means of siRNAs and shRNAs has
emerged as a promising therapeutic approach against HIV-1 [40].
However, the design of highly efficient and specific siRNAs and
shRNAs still remains critical. This is mainly due to the absence of
a standard algorithm for the design of siRNAs [41,42]. We
generated an HIV-directed shRNA library based on the proviral
DNA of HIV-1 (NL4.3), in order to systematically identify efficient
HIV-1 specific shRNAs. Our study is the first application of a
randomly engineered shRNA-library technology on the human
immunodeficiency virus (Fig. 1). The proviral DNA of HIV-1 was
fragmented using DNase I (Fig. 1a) in order to yield diverse
overlapping cDNA-fragments [31,32]. A stringent fourfold
selection protocol based on positive selection via blasticidin,
puromycin and EGFP fluorescence as well as negative selection by
means of ganciclovir/HSV-TK in selection cell lines was applied
and enabled us to enrich for cell lines expressing potent inhibitory
shRNAs (Fig. 2). Besides their efficiency our sequences were
devoid of any detectable cytotoxicity, which is probably also due to
the stringent selection procedure (Fig. 4).
By comparing these sequences with published shRNAs, we
could show that the selection of our randomized shRNA-library
indeed identified efficient shRNAs with a comparable inhibitory
potential (Fig. 5). Many published siRNAs or shRNAs were
designed according to publicly available in silico algorithms.
Surprisingly, none of our sequences satisfied all parameters of
them. Certainly, more shRNA-sequences from randomized
libraries have to be analysed to determine general sequence
preferences. However, these functionally but not structurally
selected shRNAs may contribute to a better understanding of the
critical parameters for the design of potent siRNA and shRNA
sequences. Moreover, this information could be combined with
studies concerning the secondary structure and therefore the
accessibility of the target-mRNA, which also influences the
potential of RNAi. For this purpose Jakobsen et al. generated a
sense and antisense oligonucleotide RNA-library to identify
accessible target sites in the HIV-1 leader sequence, which is
considerably structured, and identified five particular sites [43].
It has been shown that the activity of a lentiviral vector
combining 2–3 anti-HIV shRNAs was markedly reduced with the
increasing number of shRNA expression cassettes [39] based on
recombination of repeat sequences in shRNA expression cassettes.
We conclude, that this could be abrogated using different
polymerase III promoters. Here, we could show that the shRNAs
Table 2. Specificity of shRNAs against HIV-1.
shRNA target sequence (pNL4.3) Starting nt Los Alamos hits
g 1 agctaccataatgatacaga 1454 7288
g/p 1 tcagagcagaccagagccaa 1642 8767
g/p 2 ccaccagaagagagcttcag 1668 9767
g/p 3 gagacaacaactccctctca 1699 35180
g/p Slip ctgagagacaggctaattt 1722 45201
g/p 4 gacaacaactccctctcaga 1749 10211
g/p 5 acaactccctctcagaagca 1753 3583
g/p 6 acagcgacccctcgtcacaa 1771 10267
g/p 7 tctgagagggagttgttgtc 1816 65399
g/p 8 tacaggagcagatgatacag 1873 66221
g/p 9 gtacagcctatagtgctgcc 2816 43997
g/p 10 acagctggactgtcaatgac 2822 34735
g/p 11 gtcaatgacatacagaaatt 2855 35518
g/p 12 ggcaagtcagatttatgcag 2893 33484
g/p 13 gaagcagagctagaactggc 2987 27153
g/p 14 acagagtattggcaagcaac 3302 60013
g/p 15 agagtattggcaagccacct 3304 3986
g/p 17 gagtgggagtttgtcaatac 3322 3579
g/p 18 gtcaatacccctcccttagt 3344 3456
g/p 19 actttctatgtagatggggc 3410 2931
g/p 20 aaagttgtccccctaacgga 3487 25962
g/p 22 ccagcacacaaaggaatt 4114 2825
g/p 23 ggacaagtagactgtagccc 4384 2554
g/p 24 agtactacagttaaggccgc 4142 30137
g/p 26 gtcaaggagtaatagaatct 4215 3121
vif 1 tggttttatagacatcacta 4698 3034
vif 2 gaacaagccccagaagacca 5108 4591
rev E1 gagctcatcagaacagtcag 5545 4545
env 1 tccaggcaagaatcctggct 7487 12141
a) Designation of the identified shRNAs b) shRNA-target sequence of the HIV-1
proviral clone pNL4.3 c) starting nucleotide of the shRNA based on +1 being
the transcriptional start site. d) Number of known isolates which include the
target sequence.
doi:10.1371/journal.pone.0013172.t002
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from different polymerase III promoters (Fig. 5). This suggests
them as promising candidates for multiple shRNA approaches.
Although, retroviral shRNA gene therapy approaches showed
only moderate success in the case of patients suffering from X-
linked SCID [44], the durable potential of related vector systems is
undeniable. Furthermore, siRNAs, e.g. against VEGF to combat
AMD (age-related macula degeneration) [45], cytomegalovirus
retinitis [46] and RSV infections (respiratory syncitical virus) [47]
are currently being validated in clinical phase III trials,
highlighting the significance of RNA-based therapeutics [48].
Thus, we liked to examine if our selected shRNAs would be
suitable for a gene therapeutic approach against HIV-1.
Therefore, we subcloned a range of our selected shRNAs into
the lentiviral vector pL and stably transduced them into HIV-1
permissive HeLa P4 cells at a low multiplicity of infection (MOI:
0.1) to obtain low copy integrants and reduce the risk of insertional
mutagenesis. After HIV-1 infection, all HeLa P4 cell lines stably
expressing a HIV-1 specific shRNA showed a considerable
reduction in progeny virus release in comparison to scrambeled
shRNA expressing or parental cells by inhibiting the production of
progeny virus.
It has been shown that more than one shRNA against HIV-1 is
necessary to circumvent the generation of viral escape mutants
Figure 4. Convertibility of the shRNA-library species and cellular tolerance of siRNA and lentiviral shRNA derivatives. a) 11 individual
shRNAs were chemically synthesized as siRNAs and co-transfected (5 nM, 20 nM and 100 nM) with the corresponding HSV-TK selection construct into
HEK 293 FT cells. Western blot analysis with a HSV-TK specific antibody 48h p.t. revealed that the synthetic siRNAs efficiently inhibit HSV-TK
expression in a dose-dependent manner. Hsp70 was used as loading control. b) IFN-b ELISAs were performed with HeLa cells transfected with siRNAs
or poly (I:C). None of the siRNAs induced any detectable amounts of IFN-b. c) The same sequences were stably expressed as lentiviral shRNAs in the
HIV-1 permissive HeLa P4 cells. Individual clones were infected with HIV-1 and the production of p24 was determined via ELISA 42 h p.i.. d) The
viability of the clones was determined at the indicated time points using crystal violet, demonstrating no detrimental effects of shRNA expression.
Error bars indicate +/2 SD of mean of three independent experiments.
doi:10.1371/journal.pone.0013172.g004
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three siRNAs directed against the co-receptor for HIV CCR5 and
the viral vif and tat genes resulted in a significant suppression of
HIV-1 infections in humanized mouse models [49]. Moreover, as
an optimal strategy to prevent the emergence of escape mutants, it
has been recently proposed to combine a polymerase III driven
shRNA targeting the shared exon of tat and rev in combination
with a TAR decoy and a chimeric VA1-ribozyme targeting human
CCR5 [50]. Indeed, a pilot feasibility study using this gene
therapeutic approach is already underway [48]. We suggest that
e.g. a combination of our shRNAs vif1 or vif2 with the gag/pol
shRNAs could target all alternatively spliced viral mRNAs and
thus might provide a strong defence against HIV escape mutants
(Fig. 3, Table 2). Nevertheless, a putative application of shRNA
approaches would greatly benefit from the development of
efficient non-integrating but stable vectors. Additionally, the
present expression systems could be optimized by the use of
inducible or lineage-specific promoters that drive the shRNA
expression [51,52,53], thereby reducing possible off-target or
mutagenic effects.
Recently, three whole genome screens used siRNA libraries to
identify host genes critical for HIV infections [54,55]. These
screens have suggested hundreds of previously unrecognized host
cell genes being involved in viral propagation and replication and
hence should be considered in future approaches. Although a few
HIV-specific shRNAs have been previously described, the
increased numbers of potent and non-toxic shRNAs are probably
needed to identify an optimal set of inhibitory sequences. This is
especially true in light of the fact that shRNAs can mediate
unintentional sequence-specific and –unspecific silencing of non-
targeted genes. Our study clearly demonstrates that a stringently
selected shRNA-library is well suited for the unbiased identifica-
tion of novel potent and non-toxic shRNAs in addition to those
predicted by commonly used public algorithms.
Figure 5. Expression of the shRNAs from different polymerase III promoters. a) 6 potent shRNA sequences were subcloned to allow for U6
promoter driven shRNA expression. U6 or H1 promoter expression vectors and pNL4.3LucR-E- were co-transfected into HEK 293 FT cells. Western blot
analysis with a HIV-1 Integrase specific antibody 48 h p.t. indicated that the shRNAs can be efficiently expressed from both polymerase III promoters.
Actin was used as loading control. b) c) Published shRNA-sequences against pol, nef, rev/env, gag and vpu/env were cloned to be expressed by the
U6 promoter. These constructs as well as 14 library shRNAs and pNL4.3LucR-E- were co-transfected into HEK 293 FT cells and analysed 48 h post
transfection. Western blot analysis b) with a HIV-1 Integrase specific antibody or c) luciferase assays demonstrated that the newly identified shRNAs
are as potent as the published shRNAs. A scrambled shRNA (sh scr) and non-transfected cells were used as controls.
doi:10.1371/journal.pone.0013172.g005
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